April 27 (Reuters) – Medical equipment maker Thermo Fisher Scientific said on Monday it would sell its microbiology business to private equity firm Astorg for about $1.08 billion.
• Deal consists of cash and a $50 million seller note.
• The microbiology business supplies antimicrobial susceptibility testing and culture media products used for clinical, pharmaceutical and food safety applications.
• The unit, a part of Thermo Fisher’s specialty diagnostics segment, recorded $645 million in revenue in 2025.
• “The transaction reflects our active management of the company and provides additional capital we can deploy to create shareholder value,” said Marc Casper, chief executive officer of Thermo Fisher.
• The company expects the transaction to close in the second half of 2026.
• Thermo Fisher expects the deal to be dilutive to adjusted earnings per share by $0.15 in the first full year after it closes.
• The company said it would provide details on the expected impact to its 2026 forecast during its second quarter earnings call.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
Comments